The controversy over prostate cancer screening does not appear to be going away any time soon.
Pudendal neuromodulation system shows promise for urinary incontinence
Interim data from the study showed that at 6 months following implantation, 80% (4 of 5) of evaluable women with mixed UI experienced a complete resolution of incontinence episodes.
Dr. Schwen on focal therapies for prostate cancer
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
AUGS Clinical Consensus Statement on Postoperative Urinary Retention
Postoperative urinary retention is a common outcome after surgical procedures for pelvic organ prolapse and stress urinary incontinence.
Speaking of Urology: Liquid biopsy in prostate cancer
In this episode, David M. Albala, MD, and Sanoj Punnen, MD, discuss precision medicine and the use of biomarker tests in prostate cancer screening and detection.
Tumor biology may affect response to kidney cancer treatment, study finds
In total, the investigators assessed data from 886 patients with advanced kidney cancer who were randomly assigned to receive avelumab plus axitinib or subitinib.
Information and Guidance on the Adoption of Surgical Innovation and Technology in Urogynecology
The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.
2 Commerce Drive Cranbury, NJ 08512